

SR46349-B, a 5-HT_{2A/2C} Receptor Antagonist, Potentiates Haloperidol-induced Dopamine Release in Rat Medial Prefrontal Cortex and Nucleus Accumbens

Stefania Bonaccorso, M.D., Herbert Y. Meltzer, M.D., Zhu Li, Ph.D., Jin Dai, M.D., Anna R. Alboszta, B.S., and Junji Ichikawa, M.D., Ph.D.

The combination of M100907, a putative antipsychotic drug (APD) and serotonin (5-HT)_{2A} antagonist, and the typical APD haloperidol, can enhance dopamine (DA) release in rat medial prefrontal cortex (mPFC), an effect which has been postulated to be of value to improve cognition and negative symptoms. The present study demonstrated that another putative APD and 5-HT_{2A/2C} antagonist, SR46349-B (10 mg/kg, but not 1–3 mg/kg) alone, but not M100907 (0.1 and 3 mg/kg) alone, increased mPFC DA release, whereas neither drug alone affected nucleus accumbens (NAC) DA release. Neither SR46349-B nor M100907 alone affected nucleus accumbens (NAC) DA release. SR46349-B (3 mg/kg) potentiated haloperidol-induced DA release in both regions, whereas M100907 (0.1 mg/kg) potentiated haloperidol (0.1 mg/kg)-induced mPFC DA release and inhibited it in the NAC. WAY100635 (0.2 mg/kg), a 5-HT_{1A} antagonist,

abolished the effects of haloperidol plus M100907 as well as SR46349-B on DA release in the mPFC, but did not do so in the NAC. Thus, 5-HT_{2A} and 5-HT_{2A/2C} antagonism together with haloperidol-induced D₂ antagonism may potentiate mPFC DA release via 5-HT_{1A} agonism, whereas the combined effects of these agents on NAC DA release is not dependent upon 5-HT_{1A} receptor stimulation. Interestingly, similar to the effect of SR46349-B, high dose M100907 (3 mg/kg), which might have antagonist activity at 5-HT_{2C} receptors, potentiated 1 mg/kg haloperidol-induced DA release in the mPFC and NAC. These results suggest that 5-HT_{2A/2C} antagonism may be more advantageous than selective 5-HT_{2A} antagonism as an adjunct to D₂ antagonists to improve cognition and negative symptoms in schizophrenia. [Neuropsychopharmacology 27:430–441, 2002] © 2002 American College of Neuropsychopharmacology. Published by Elsevier Science Inc.

From the Division of Psychopharmacology, Departments of Psychiatry and Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37212, USA.

Address correspondence to: Dr. J. Ichikawa, 1601 23rd Avenue South, The First Floor Laboratory R-1117, The Psychiatric Hospital at Vanderbilt, Nashville, TN 37212. Tel.: (615) 327-7242; Fax: (615) 322-2522; E-mail: ichikaj@ctrvax.vanderbilt.edu

Received October 31, 2001; revised February 5, 2002; accepted February 14, 2002.

Online publication: 2/25/02 at www.acnp.org/citations/Npp022502247.

KEY WORDS: 5-HT_{2A} receptor antagonism; 5-HT_{2C} receptor antagonism; 5-HT_{1A} receptor agonism; Haloperidol; Dopamine release; Medial prefrontal cortex; Nucleus accumbens

Potent serotonin (5-HT)_{2A} antagonism, in relation to weaker dopamine (DA) D₂ receptor antagonism, has been suggested to distinguish the atypical antipsychotic drugs (APD) such as clozapine, quetiapine, olanzapine, risperidone, and ziprasidone, from the typical APDs haloperidol or S(-)-sulpiride, and to be a major factor contributing to their antipsychotic action and low liability of causing extrapyramidal symptoms (EPS) (Meltzer

et al. 1989; Schotte et al. 1996; Ichikawa and Meltzer 1999a; Meltzer 1999). The atypical APDs have a greater ability than the typical APDs to increase cortical DA release in rodents and non-human primates (Moghaddam and Bunney 1990; Li et al. 1998; Kuroki et al. 1999), which may contribute to their greater ability to improve negative and cognitive symptoms in patients with schizophrenia (Meltzer and McGurk 1999), although other factors may also contribute; e.g. adrenergic (Hertel et al. 1999) and muscarinic cholinergic mechanisms (Goff et al. 1995; Bymaster et al. 1999; Tandon 1999; Ichikawa et al. 2002).

Clozapine, olanzapine, and risperidone, all of which are 5-HT_{2A} and D₂ receptor antagonists, enhance DA release in rat medial prefrontal cortex (mPFC), and this effect has been shown to be related to the combined 5-HT_{2A} and D₂ receptor blockade (Kuroki et al. 1999; Ichikawa et al. 2001a,b). We have also found that the selective 5-HT_{2A} receptor antagonist M100907 (Carr et al. 1991; Kehne et al. 1996) potentiated the ability of low (0.1 mg/kg), but not high dose (1 mg/kg) haloperidol to increase DA release in the mPFC, and that M100907, reciprocally, inhibited the ability of both doses of haloperidol to increase DA release in the nucleus accumbens (NAC) (Liégeois et al. 2002). Thus, when a 5-HT_{2A} receptor antagonist is combined with typical APDs such as haloperidol, which is devoid of appreciable 5-HT_{2A} receptor antagonism *in vitro* and *in vivo* (Meltzer et al. 1989; Stockmeier et al. 1993; Matsubara et al. 1993; Schotte et al. 1996), it would be expected to produce increases in cortical DA release comparable to atypical APDs. Interestingly, ritanserin, a mixed 5-HT_{2A/2C} receptor antagonist (Roth et al. 1992), has been reported to potentiate the D_{2/3} receptor antagonist raclopride-induced DA release in the mPFC and NAC, but not striatum (STR) (Andersson et al. 1995). It has also been reported that ritanserin and M100907 both potentiated the raclopride-induced conditioned avoidance response (CAR) in rats, a model for antipsychotic action (Andersson et al. 1995; Wadenberg et al. 1998). M100907 also potentiated haloperidol-induced CAR following its systemic or direct administration into either the mPFC or NAC (Hicks et al. 1999; Wadenberg et al. 2001). Taken together, these results suggest that 5-HT_{2A} receptor antagonism may increase antipsychotic effects of typical APDs such as haloperidol, which lack appreciable affinity for the 5-HT_{2A} receptor (Ichikawa and Meltzer 1999a; Meltzer 1999).

Recent microdialysis studies have suggested different and sometimes opposite effects of 5-HT_{2A} and 5-HT_{2C} receptor on cortical, striatal, and NAC DA release (Ichikawa and Meltzer 1999a; Di Matteo et al. 2001). For example, the selective 5-HT_{2C} receptor antagonist SB242084 increased DA release in the mPFC (Millan et al. 1998) and NAC (Di Matteo et al. 1999, 2000a,b; Gobert et al. 2000), but not the STR (Di Matteo et al.

1999), whereas M100907 had no effect on DA release in either the mPFC or the NAC (Gobert and Millan 1999; Ichikawa and Meltzer 2000; Rollema et al. 2000; Zhang et al. 2000; Ichikawa et al. 2001a,b; Pehek et al. 2001; Westerink et al. 2001; Liégeois et al. 2002). The selective 5-HT_{2C} receptor agonist Ro 60-0175 decreased DA release in the mPFC (Gobert et al. 2000; Ichikawa et al. 2001b) and NAC (Di Matteo et al. 1999, 2000a,b), but not STR (Di Matteo et al. 1999), whereas 5-HT_{2A} receptor stimulation by DOI, a 5-HT_{2A/2C} receptor agonist, increased DA release in the mPFC (Gobert and Millan 1999; Ichikawa et al. 2001b) and NAC (Yan 2000; Yan et al. 2000).

Another 5-HT_{2A} and possibly also 5-HT_{2C} receptor antagonist, SR46439-B (IC₅₀ = 120 nM for 5-HT_{2C} receptors in pig cortex, and 5.8 nM for 5-HT_{2A} receptors in rat cortex, Rinaldi-Carmona et al. 1992), which alone had no effect on DA release in the STR, has been reported to inhibit the ability of haloperidol (0.01, but not 0.1 or 1.0, mg/kg) to increase striatal DA release (Spampinato et al. 1998; Lucas and Spampinato 2000). However, there are no data on its effect on basal and haloperidol-induced DA release in the mPFC and NAC. SR46349-B may be effective in the treatment of schizophrenia (Arvarytis L, personal communication), while the therapeutic effects of M100907 (Shiple 1998; Talvik-Lotfi et al. 2000) and ritanserin (Wiesel et al. 1994) are not so apparent. Therefore, it is of considerable interest whether SR46349-B has an effect on basal and haloperidol-induced DA release in the mPFC and NAC similar to that of M100907, ritanserin, or not.

We have also suggested that the atypical APDs, such as clozapine, olanzapine, and risperidone, increase DA release in the mPFC, at least in part, via 5-HT_{1A} receptor stimulation, because 5-HT_{1A} receptor agonist R(+)-8-OH-DPAT dose-dependently increases DA release in the mPFC, and WAY100635, a selective 5-HT_{1A} receptor antagonist, inhibits those effects of R(+)-8-OH-DPAT and the three atypical APDs (Ichikawa et al. 2001a). The facilitation of 5-HT_{1A} receptor stimulation by clozapine, olanzapine, and risperidone regarding the effect on DA release in the mPFC may be associated with their concomitant blockade of 5-HT_{2A} and D₂ receptors. In this regard, M100907, a selective 5-HT_{2A} receptor antagonist, potentiated the D_{2/3} receptor antagonist S(-)-sulpiride-induced DA release in the mPFC, an effect completely abolished by WAY100635 (Ichikawa et al. 2001a). Therefore, it is possible that, as has been shown by the combination with M100907 (Liégeois et al. 2002), 5-HT_{2A} receptor antagonism by SR46349-B also potentiates the ability of haloperidol to produce minimal increases in DA release in the mPFC. It is also possible that these potentiations by M100907 and SR 46349-B are mediated via functional 5-HT_{1A} receptor agonism due to combined 5-HT_{2A} and D₂ receptor blockade (Ichikawa et al. 2001a).

The present study examined the effect of SR46349-B, a 5-HT_{2A} receptor antagonist, on basal and haloperidol-induced DA release in the mPFC and NAC, compared with the effects of M100907. We also tested the hypothesis that SR46349-B as well as M100907 affects the ability of haloperidol to increase DA release in the mPFC and NAC via 5-HT_{1A} receptor-dependent mechanism(s).

METHODS AND MATERIALS

Animals

Male Sprague-Dawley albino rats (Zivic-Miller Laboratories, Porterville, PA) weighing 250 to 350 g were housed two to three per cage and maintained in a controlled 12:12-h light-dark cycle (lights on at 7:00 A.M.) and under constant temperature at 22°C, with free access to food and water.

Surgery and Microdialysis

The procedure employed here has been reported elsewhere (Ichikawa et al. 2001a,b). In brief, three to five days following cannulation surgery under anesthesia with a combination of xylazine (13 mg/kg, Rompun; Shawnee Mission, KS) and ketamine HCl (87 mg/kg, Ketaset; Fort Dodge Laboratories, Fort Dodge, IA), a dialysis probe (2 mm membrane length) was implanted into the mPFC and NAC. Stereotaxic coordinates of probe, when implanted, are A +3.2, L -0.8, V -5.5 mm for the mPFC, and A +2.0, L +1.5, V -7.5 mm for the NAC, respectively, relative to bregma (Paxinos and Watson 1986). A catheter constructed from microbore Tygon tubing (TGY-010; Small Parts Inc., Miami Lakes, FL) was implanted subcutaneously in the back of rats. After the overnight perfusion (0.4 μ l/min) of the probe, the flow rate was increased to 1.5 μ l/min, and dialysate samples were collected every 30 min. The perfusion medium was Dulbecco's phosphate buffered saline solution (Sigma, St. Louis, MO) including Ca²⁺ (138 mM NaCl, 8.1 mM Na₂HPO₄, 2.7 mM KCl, 1.5 mM KH₂PO₄, 0.5 mM MgCl₂, 1.2 mM CaCl₂, pH 7.4). The location of the dialysis probes was verified with 100 μ m brain slices (OTS-4000; FHC, Bowdoinham, ME). The Institutional Animal Care and Use Committee of Vanderbilt University approved the procedure applied in these experiments.

Biochemical Assay

Dialysate samples (45 μ l/30 min) were directly applied onto a HPLC with a 20 μ l sample loop and analyzed for DA with a Millennium chromatogram manager (Waters, Milford, MA). DA was separated on a C18 reversed phase column (BDS Hypersil, 3 μ m, 1 \times 100 mm; Keystone Scientific, Bellefonte, PA) at 35°C. The

mobile phase consisted of 48 mM anhydrous citric acid and 24 mM sodium acetate trihydrate containing 0.5 mM EDTA-Na₂, 10 mM NaCl, 2 mM dodecyl sulfate sodium salt (Acros, Pittsburgh, PA) and 17% (v/v) acetonitrile, adjusted to pH 4.8 with concentrated NaOH, and was pumped at 0.05 ml/min (LC-10AD; Shimadzu, Kyoto, Japan). DA was detected by a 3-mm glassy carbon unijet working electrode (MF-1003, BAS) set at +0.58 V (LC-4C, BAS) versus an Ag/AgCl reference electrode.

Drugs

WAY100635 (Sandoz, Basel, Switzerland) was dissolved in deionized water. Haloperidol (McNeil, Spring House, PA) and M100907 (Hoechst Marion Roussel, NJ) were dissolved in 0.1 M tartaric acid solution, which was adjusted to pH 6–7 with NaOH. SR46349-B (Sanofi, Montpellier, France) was dissolved in 45% 2-hydroxypropyl- β -cyclodextrin (Research Biochemical Inc., Natick, MA). Vehicle or drugs were administered through the indwelling subcutaneous catheter.

Data Analysis

Only results derived from healthy rats with correctly positioned dialysis probes were included in the data analysis. Mean pre-drug baseline levels (time -90 min, -60 min, -30 min and 0) were designated as 100%. The net-AUC (area under the curve) was calculated from the absolute net increase for a 180-min period (six samples) after subtracting each pre-drug baseline value. The %net-AUC is the net-AUC value expressed as a percentage of each baseline AUC value. Repeated measure ANOVA followed by Fisher's protected least significant difference post-hoc pairwise comparison procedure was used to determine group differences (StatView 4.5 for the Macintosh). A $p < .05$ was considered significant in this study. All results are reported as mean \pm SE

RESULTS

Basal concentrations of DA in the dialysate (fmol/20 μ l) were 2.40 ± 0.11 ($n = 83$) in the mPFC and 21.3 ± 1.0 ($n = 82$) in the NAC, respectively. There were no significant differences in basal DA concentrations in the mPFC and NAC between treatment groups.

SR46349-B (10 mg/kg, but not 1 or 3 mg/kg) increased DA release in the mPFC, but had no effect on that in the NAC at all doses tested (Figure 1, panels A and B). SR46349-B (1 and 3 mg/kg) dose-dependently potentiated the haloperidol (0.1 mg/kg)-induced DA release in the mPFC and NAC, although only the effect of the 3 mg/kg dose reached significance in the NAC (Figure 2, panels A and B). SR46349-B (1 mg/kg) signif-

SR46349B, WAY100635, M100907




Figure 1. The time-course effect of SR46349-B (SR) and M100907 (M), selective 5-HT_{2A} receptor antagonists, and WAY100635 (WAY), a selective 5-HT_{1A} receptor antagonist, followed by vehicle (VEH). A. SR markedly increased DA release in the mPFC at 10 mg/kg (∇ , $F_{1,9} = 12.74$, $p = .006$), but not at 1 mg/kg (\circ , $F_{1,11} = 0.63$, $p = .44$) or 3 mg/kg (\bullet , $F_{1,9} = 4.65$, $p = .060$), compared with VEH (\square). However, there was a significant difference ($F_{1,9} = 6.56$, $p = .031$) between the effect of 3 mg/kg and that of VEH when compared at 30, 60, 90 and 120 min following SR. B. SR (1, 3, and 10 mg/kg) had no significant effect on DA release in the NAC (\circ , $F_{1,11} = 0.64$, $p = .44$; \bullet , $F_{1,10} = 3.10$, $p = .11$; or ∇ , $F_{1,9} = 2.38$, $p = .16$, respectively), compared with VEH (\square). C, D. WAY (0.2 mg/kg, \circ) or M (0.1 mg/kg, \bullet) had no significant effect on DA release in the mPFC and NAC, compared with VEH (\square). $n = 4-7$.

icantly potentiated high dose haloperidol (1 mg/kg)-induced DA release in the mPFC and NAC (Figure 2, panels C and D). The potentiation by SR46349-B (1 mg/kg) of haloperidol (0.1 mg/kg)-induced DA release in the mPFC was completely abolished by WAY100635 (0.2 mg/kg) (Figure 3, panel A). However, WAY100635 (0.2 mg/kg) did not significantly affect the potentiation by SR46349-B (1 mg/kg) of haloperidol (0.1 mg/kg)-induced DA release in the NAC (Figure 3, panel B). Similarly, M100907 (0.1 mg/kg) potentiated haloperidol (0.1 mg/kg)-induced DA release in the mPFC. This potentiation by M100907 was completely abolished and further significantly decreased below vehicle controls by WAY100635 (0.2 mg/kg) (Figure 3, panel C). WAY100635 (0.2 mg/kg) had no effect on the ability of M100907 (0.1 mg/kg) to inhibit haloperidol (0.1 mg/kg)-induced DA release in the NAC (Figure 3, panel D). Analysis of the %net-AUC of the above-mentioned effects on DA release clearly showed the dose-relationship and regional differences in the mPFC and NAC (Figure 4).

Interestingly, similar to the effect of SR46349-R, high dose M100907 (3 mg/kg) potentiated the ability of high dose haloperidol (1 mg/kg) to increase DA release in the mPFC and NAC (Figure 5). M100907 (3 mg/kg) alone had no significant effect on DA release in either region.

DISCUSSION

The major findings in this study are that SR46349-B by itself increased basal DA release in the mPFC, but not the NAC, and that SR46349-B potentiated haloperidol-induced DA release in the mPFC and NAC. The potentiation by SR46349-B and M100907 of haloperidol-induced DA release in the mPFC was completely abolished by the 5-HT_{1A} receptor antagonist WAY100635.

Effects on Basal DA Release

High dose (10 mg/kg), but not low dose (1 or 3 mg/kg) SR46349-B significantly increased DA release in the




Figure 2. The time-course effect of SR46349-B (SR), a selective 5-HT_{2A} receptor antagonist, haloperidol (HAL) and their combination. A, B. HAL (0.1 mg/kg, ○) significantly increased DA release in the mPFC ($F_{1,11} = 29.37, p < .001$) and NAC ($F_{1,9} = 48.46, p < .001$), respectively, compared with vehicle controls (VEH, □). SR (1 mg/kg, ●, and 3 mg/kg, ▽), given 30 min prior to HAL, significantly increased the ability of HAL (0.1 mg/kg) to increase DA release in the mPFC ($F_{1,12} = 13.19, p = .003$; and $F_{1,13} = 54.82, p < .001$, respectively) and NAC (3 mg/kg, $F_{1,9} = 15.11, p = .004$; but not 1 mg/kg, $F_{1,10}, p = .067$), respectively, compared with the effect of HAL itself (○). C, D. HAL (1 mg/kg, ○) significantly increased DA release in the NAC ($F_{1,9} = 9.72, p = .012$), but not mPFC ($F_{1,10} = 1.44, p = .26$), compared VEH (□). SR (1 mg/kg, ●), given 30 min prior to HAL, significantly increased the ability of HAL (1 mg/kg) to increase DA release in the mPFC ($F_{1,8} = 32.79, p < .001$) and NAC ($F_{1,9} = 5.22, p = .048$), respectively, compared with the effect of HAL itself (○). $n = 4-8$.

mPFC, similar to the effect of ritanserin, a 5-HT_{2A/2C} receptor antagonist, which is also a DA uptake inhibitor (Ruiu et al. 2000), at high (3 and 5 mg/kg) but not low doses (1, 1.5, and 2 mg/kg) (Nomikos et al. 1994; Pehek 1996). These effects of high dose SR46349-B and ritanserin to increase cortical DA release may be due mostly to 5-HT_{2C} receptor blockade since SR46349-B has moderate in vitro affinity for 5-HT_{2C} receptors ($IC_{50} = 120$ nM in pig cortex), compared with 5-HT_{2A} receptors ($IC_{50} = 5.8$ nM in rat cortex) (Rinaldi-Carmona et al. 1992), and the selective 5-HT_{2C} receptor antagonist SB242084 has been reported to increase DA release in

the mPFC (Millan et al. 1998) and NAC (Di Matteo et al. 1999; Gobert et al. 2000). The lack of an effect of SR46349-B (1, 3, and 10 mg/kg) on DA release in the NAC in the present study is consistent with the data of De Deurwaerdère and Spampinato (1999) and Di Giovanni et al. (1999, 2000). The difference between SR46349-B and SB242084 may be due to the potent 5-HT_{2A} receptor antagonism of SR46349-B. On the other hand, M100907, a selective 5-HT_{2A} receptor antagonist ($K_i = 0.36$ nM for 5-HT_{2A}}, and 105 nM for 5-HT_{2C} receptors, respectively; Carr et al. 1991), has been reported not to affect DA release in either the mPFC or the NAC




Figure 3. The time-course effect of WAY100635 (WAY), a selective 5-HT_{1A} receptor antagonist, SR46349-B (SR) and M100907 (M), selective 5-HT_{2A} receptor antagonists, haloperidol (HAL) and their combination. A, B. WAY (0.2 mg/kg), given 5 min prior to SR, abolished HAL (0.1 mg/kg, ○)-induced DA release enhanced by SR (1 mg/kg) in the mPFC (▽, $F_{1,10} = 7.83, p = .019$), but not NAC (▽, $F_{1,11} = 1.71, p = .22$), compared with the effect of a combination of SR and HAL (●). C, D. M (0.1 mg/kg), given 30 min prior to HAL, increased the ability of HAL (0.1 mg/kg) to increase DA release in the mPFC (●, $F_{1,12} = 13.76, p = .003$), but inhibited that in the NAC (●, $F_{1,10} = 33.42, p < .001$), compared with the effect of HAL itself (○). WAY (0.2 mg/kg), given 5 min prior to M, abolished HAL (0.1 mg/kg)-induced DA release enhanced by M (0.1 mg/kg) in the mPFC (▽, $F_{1,10} = 25.64, p < .001$), compared with the effect of a combination of M and HAL (●), and further decreased DA release ($F_{1,10} = 9.78, p = .011$), compared with the effect of HAL alone (○). WAY (0.2 mg/kg) had no effect on HAL (0.1 mg/kg)-induced DA release inhibited by M (0.1 mg/kg) in the NAC (▽), compared with the effect of a combination of SR and HAL (●). n = 4–8.

(present data; Gobert and Millan 1999; Ichikawa and Meltzer 2000; Rollema et al. 2000; Zhang et al. 2000; Ichikawa et al. 2001a,b; Pehek et al. 2001; Westerink et al. 2001; Liégeois et al. 2002). Thus, it is possible that the difference between SR46349-B and M100907 in their abilities to affect basal as well as haloperidol-induced DA release in the mPFC and NAC is due, at least in part, to blockade of 5-HT_{2C} receptors by SR46349-B, but not by M100907.

Effects on Haloperidol-induced DA Release in the mPFC

We have reported that low (0.1 mg/kg), but not high dose (1 mg/kg), haloperidol significantly increased DA release in the mPFC, while both doses significantly increased DA release in the NAC (Liégeois et al. 2002), most likely due to D₂ receptor blockade. The evidence that both SR46349-B (1 and 3 mg/kg) and M100907 (0.1 mg/kg) potentiated low dose haloperidol (0.1 mg/kg)-induced




Figure 4. Analysis of the %net-AUC (area under the curve) provides direct comparison of dose related effects of haloperidol (HAL, 0.1 and 1 mg/kg) in combination with SR46349-B (SR, 1, ○; and 3 mg/kg, □), M100907 (M, 0.1 mg/kg, ▽) and WAY100635 (W, 0.2 mg/kg, ▼). SR (1 and 3 mg/kg), a selective 5-HT_{2A} receptor antagonist, potentiated HAL (0.1 and 1 mg/kg)-induced DA release in the mPFC and NAC. M (0.1 mg/kg), a selective 5-HT_{2A} receptor antagonist, potentiated HAL (0.1 mg/kg)-induced DA release in the mPFC, but inhibited that in the NAC. WAY (0.2 mg/kg) completely abolished the potentiation effect of SR (1 mg/kg) and M (0.1 mg/kg) on HAL (0.1 mg/kg)-induced DA release in the mPFC. WAY (0.2 mg/kg) did not affect the effect of either SR (1 mg/kg) or M (0.1 mg/kg) on HAL (0.1 mg/kg)-induced DA release in the NAC. * indicates significant difference from the effect of HAL alone (■). † indicates significant difference from the effect of a combination of HAL with SR or M. n = 4–8.

DA release in the mPFC suggests that the potentiation may be due to the combined effects of 5-HT_{2A} and D₂ receptor blockade (Ichikawa et al. 2001a,b). The nearly identical potentiation by 0.1 mg/kg M100907 and 1 mg/kg SR36349-B of 0.1 mg/kg haloperidol-induced DA release in the mPFC indicates that 1 mg/kg SR46349-B may be equivalent to 0.1 mg/kg M100907 as a 5-HT_{2A} receptor antagonist in vivo. Reversal by WAY100635 (0.2 mg/kg), a selective 5-HT_{1A} receptor antagonist, of the potentiation by SR46349-B (1 mg/kg) and M100907 (0.1 mg/kg) supports our hypothesis that facilitation of 5-HT_{1A} receptor stimulation is essential to the combined blockade of 5-HT_{2A} and D₂ receptor to increase DA release in the mPFC (Ichikawa et al. 2001a). Interestingly, WAY100635 (0.2 mg/kg) significantly decreased the effect of M100907 (0.1 mg/kg) plus haloperidol (0.1 mg/kg) on DA release in the mPFC below the effect of haloperidol alone. However, it is unlikely that the effect of low dose haloperidol by itself to increase DA release in the mPFC is due to 5-HT_{1A} receptor stimulation because WAY100635 did not further decrease the effect of haloperidol alone on DA release in the mPFC, when combined with SR46349-B.

It is noteworthy that SR46349-B (1 mg/kg) also potentiated high dose (1 mg/kg) haloperidol-induced DA

release in the mPFC, which contrasts the lack of effect of M100907 (0.1 mg/kg) to do so (Liégeois et al. 2002). Although the mechanism by which haloperidol (0.01–1 mg/kg) produces an inverted U-shaped increase in DA release in the mPFC is unknown (Liégeois et al. 2002), haloperidol (1 mg/kg) by itself had no effect on DA release in the mPFC. 5-HT_{2C} receptor antagonism may be relevant to the ability of SR46349-B (1 mg/kg), but not M100907 (Liégeois et al. 2002), to potentiate high dose (1 mg/kg) haloperidol-induced DA release in the mPFC. However, it should be noted that many, but not all, typical APDs, including haloperidol, as well as atypical APDs such as clozapine, are 5-HT_{2C} receptor antagonists (Roth et al. 1992), and that Ro 60-0175 (3 mg/kg), a selective 5-HT_{2C} receptor agonist, did not affect the ability of clozapine (20 mg/kg) to increase DA release in the mPFC (Ichikawa et al. 2001b). These results suggest that 5-HT_{2C} receptor antagonism may not solely contribute to the ability of clozapine and the related 5-HT_{2C} receptor antagonist APDs to increase DA release in the mPFC. Therefore, the precise mechanism by which SR46349-B potentiates high dose (1 mg/kg) haloperidol-induced DA release in the mPFC remains to be determined.




Figure 5. The time-course effect of M100907 (M), a selective 5-HT_{2A} receptor antagonist, haloperidol (HAL) and their combination. A, B. High dose M (3 mg/kg), given 30 min prior to HAL, increased the ability of high dose HAL (1 mg/kg) to increase DA release in the mPFC (●, $F_{1,10} = 7.61$, $p = .020$), compared with vehicle controls (VEH, □), although this combination did not significantly differ from the ability of HAL itself ($F_{1,10} = 3.26$, $p = .10$) or M alone ($F_{1,10} = 4.83$, $p = .053$), respectively. The same combination of M and HAL produced a significantly greater increase in DA release in the NAC, compared with the affect of HAL alone (●, $F_{1,9} = 9.04$, $p = .015$). M (3 mg/kg) by itself had no significant effects on DA release in the mPFC and NAC, compared with vehicle controls. $n = 4-6$.

Effects on Haloperidol-induced DA Release in the NAC

SR46349-B had an effect opposite to that of M100907 (0.1 mg/kg) on haloperidol-induced DA release in the NAC. SR46349-B (1 mg/kg) together with both low and high dose haloperidol (0.1 and 1 mg/kg) produced significantly greater increases in DA release in the NAC, compared with the effect of haloperidol alone. By sharp contrast, M100907 (0.1 mg/kg) inhibited both 0.1 and 1 mg/kg haloperidol-induced DA release in the NAC (present data; Liégeois et al. 2002). These differences may be attributed to the 5-HT_{2C} receptor antagonist property of SR46349-B, compared with selective 5-HT_{2A} receptor antagonism by M100907, since ritanserin, a mixed 5-HT_{2A/2C} receptor antagonist, potentiated the D_{2/3} receptor antagonist raclopride-induced DA release in the mPFC and NAC, but not STR (Andersson et al. 1995). Ritanserin has almost equivalent affinities for 5-HT_{2A} ($K_i = 3.8$ nM) and 5-HT_{2C} receptors (2.7 nM) (Roth et al. 1992), whereas M100907 is much more selective for 5-HT_{2A} receptors (Carr et al. 1991), as mentioned above. Ritanserin (1.25 mg/kg) and SR46349-B (0.5 mg/kg) have been reported to attenuate low dose (0.01 and 0.1 mg/kg), but not high dose (1 mg/kg), haloperidol-induced DA release in the STR, whereas SB206553, a 5-HT_{2B/2C} receptor antagonist, potentiated haloperidol (0.01, but not 1, mg/kg)-induced striatal DA release (Spampinato et al. 1998; Lucas et al. 2000). Interestingly, De Deurwaerdère and Spampinato

(1999) also reported that SR46349-B (0.5 mg/kg) and ritanserin (0.63 mg/kg) reversed an increase in DA release in the NAC produced by the electrical stimulation of the dorsal raphe nuclei. Thus, it appears that low dose SR46349-B (0.5 mg/kg) may be more selective for 5-HT_{2A} receptors, whereas high dose SR46349-B (1, 3, and 10 mg/kg), as in the present study, may have appreciable 5-HT_{2C} receptor antagonist properties, in vivo, as well as 5-HT_{2A} receptor antagonism. The discrepancy between the present data in the NAC and the results of others in the STR (Spampinato et al. 1998; Lucas et al. 2000) may also be due, in part, to the difference in the distribution of 5-HT_{2A} and 5-HT_{2C} receptors. 5-HT_{2A} receptors are sparsely distributed in the NAC compared with the STR (Appel et al. 1990; Morilak et al. 1993), whereas 5-HT_{2C} receptors are widely distributed in the brain (Barnes and Sharp 1999). Differences in the extent of 5-HT_{2A} and 5-HT_{2C} receptor antagonism by drugs are, therefore, important because of their differential effects on DA release in various terminal regions of the DA system.

In this regard, high dose M100907 (3 mg/kg) also potentiated high dose haloperidol (1 mg/kg)-induced DA release in the mPFC and NAC (Figure 5), whereas 0.1 mg/kg M100907 failed to affect 1 mg/kg haloperidol-induced DA release in the mPFC, but inhibited that in the NAC (present data; Liégeois et al. 2002). These results may support our hypothesis that SR46349-B (1 mg/kg) potentiated the ability of haloperidol to in-

crease DA release in the mPFC and NAC, presumably in large part, due to 5-HT_{2C} receptor antagonism or, more likely, mixed 5-HT_{2A/2C} receptor antagonism, since high dose M100907 would be expected to have also 5-HT_{2C} receptor antagonist property (K_i = 88 nM) despite its high selectivity for the 5-HT_{2A} receptor (K_i = 0.85 nM, Kehne et al. 1996). Furthermore, it should be noted that an inverse agonist activity of M100907 and some of typical and atypical APDs has been suggested to be important to their antipsychotic actions (Rauser et al. 2001; Weiner et al. 2001). M100907 also has virtually identical affinity for the sigma receptor (K_i = 87 nM, Kehne et al. 1996). However, this seems to be unlikely to contribute to the effect of high dose M100907 to potentiate haloperidol-induced DA release in the mPFC and NAC, because haloperidol is a potent sigma receptor antagonist (K_i = 1.1 nM, Schotte et al. 1996).

We have reported that R(+)-8-OH-DPAT (0.05, mg/kg), a selective 5-HT_{1A} receptor agonist, which by itself decreased basal DA release in the NAC only at high doses (0.2 mg/kg, but not 0.1 or 0.05 mg/kg), had the following effects: (1) it inhibited the clozapine (20 mg/kg) and low dose risperidone (0.01 and 0.03 mg/kg)-induced DA release in the NAC, an effect reversed by WAY100635; and (2) potentiated the ability of low dose S(-)-sulpiride (1 and 3 mg/kg), a D_{2/3} receptor antagonist, to increase DA release in the NAC; although (3) it had no effect on the ability of high dose S(-)-sulpiride (10 and 25 mg/kg) and risperidone (0.1 or 1, mg/kg), as well as all doses of haloperidol (0.01, 0.03, 0.1 and 1 mg/kg), to increase DA release in the NAC (Ichikawa and Meltzer 1999b, 2000). We also reported no effect of M100907 (1 mg/kg) on the ability of R(+)-8-OH-DPAT (0.2 mg/kg) to decrease DA release in the NAC (Ichikawa and Meltzer 2000). These results suggest that the combination of potent 5-HT_{2A} and weak D₂ receptor antagonism produced by atypical APDs may facilitate the ability of 5-HT_{1A} receptor stimulation to decrease DA release in the NAC. However, 5-HT_{1A} receptor stimulation is unlikely to be involved in either the potentiation by SR46349-B or the inhibition by M100907 of haloperidol-induced DA release in the NAC because WAY100635 had no significant effect on either of the potentiation or inhibition, although further studies may be warranted because of the slight but non-significant effect. Thus, combined blockade of 5-HT_{2A} and/or 5-HT_{2C}, and D₂ receptors may modulate DA release in the NAC, via processes independent of 5-HT_{1A} receptor stimulation, although it may be affected by additional 5-HT_{1A} receptor stimulation. Alternatively, it is further suggested that the ability of D₂ receptor blockade to increase DA release in the NAC, compared with the mPFC, may be directly affected by 5-HT_{2A} and 5-HT_{2C} receptors.

There is evidence that some 5-HT_{2A} receptor antagonists can decrease the radiolabeled drug binding to D₂

receptors. For example, ketanserin, a 5-HT_{2A} receptor antagonist, has recently been reported to dose-dependently decrease striatal binding of [¹¹C]raclopride, a D_{2/3} receptor antagonist, in the monkey, as measured by positron emission tomography (PET) scanning (Tsukada et al. 1999). The ketanserin-induced reduction of [¹¹C]raclopride binding was not due to an increase in synaptic DA concentrations, a possible cause of decreased [¹¹C]raclopride binding (Seeman et al. 1989; Dewey et al. 1993) since ketanserin produces minimal increases in striatal DA release (Tsukada et al. 1999). Raclopride, by itself, has been reported not to affect the binding of [¹¹C]M100907 in any region of the post-mortem human brain (Hall et al. 2000). Thus, it is intriguing to hypothesize that, in the NAC, M100907 decreases the blockade of presynaptic D₂ autoreceptors by haloperidol, and that SR46349-B similarly increases the affinity of haloperidol for these D₂ autoreceptors due to 5-HT_{2C} receptor antagonism, with or without 5-HT_{2A} receptor antagonism, causing an increase and decrease, respectively, of DA release in that region.

Clinical Implications

The results reported here suggest that 5-HT_{2A} receptor blockade may be an useful method to augment actions of typical APDs as well as being a key component of the action of some atypical APDs. The typical APDs such as haloperidol have limited effects on negative and cognitive symptoms of schizophrenia, compared with the superior effect of atypical APDs such as clozapine, olanzapine, risperidone, quetiapine, ziprasidone, iloperidone, and melperone (Meltzer and McGurk 1999; see the introductory paragraphs of this article). Thus, it is proposed that the addition of 5-HT_{2A} receptor antagonism (a feature common to all of the atypical APDs listed above) to haloperidol, fluphenazine, or other typical APDs, which are themselves devoid of appreciable 5-HT_{2A} receptor antagonism, may achieve at least some of the benefits of the atypical APDs; for example, facilitation of dopaminergic transmission in the cortex (suggested to be reduced in schizophrenia) and attenuation of dopaminergic transmission in the mesolimbic system (suggested to be increased in schizophrenia) (Davis et al. 1991). Specifically, M100907 inhibition of haloperidol-induced DA release in the NAC and perhaps also the potentiation of DA release in the mPFC may be relevant to its ability to potentiate haloperidol-induced CAR (Hicks et al. 1999; Wadenberg et al. 2001). Mixed 5-HT_{2A/2C} receptor antagonism may be useful for improving cognition and negative symptoms in schizophrenia when it is combined with high dose haloperidol because of increased cortical DA release, while producing more potent blockade of D₂ receptors to ameliorate psychosis. The role of 5-HT_{2C} receptor antagonism in antipsychotic action needs further clarification.

CONCLUSION

The 5-HT_{2A} receptor antagonists SR46349-B and M100907 can potentiate the ability of the typical APD haloperidol to increase DA release in the mPFC, via a 5-HT_{1A} receptor-dependent mechanism, as has been shown by the atypical APDs (Ichikawa et al. 2001a). This combination may produce some of clinically relevant effects of atypical APDs. SR46349-B differs from M100907, a more selective 5-HT_{2A} receptor antagonist, probably due to its 5-HT_{2C} receptor antagonist properties. This difference may explain the ability of SR46349-B and M100907 (0.1, but not 3, mg/kg) to respectively potentiate and inhibit haloperidol-induced DA release in the NAC, via 5-HT_{1A} receptor-independent processes.

ACKNOWLEDGMENTS

The present study was supported, in part, by Warren Medical Institute foundation.

REFERENCES

- Andersson JL, Nomikos GG, Marcus M, Hertel P, Mathe JM, Svensson TH (1995): Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectivity in the mesolimbic dopaminergic system. *Naunyn-Schmiedeberg's Arch Pharmacol* 352: 374–385
- Appel NM, Mitchell WM, Garlick RK, Glennon RA, Teitler M, De Souza EB (1990): Autoradiographic characterization of (\pm)-1-(2,5-dimethoxy 4-[¹²⁵I]iodophenyl)-2-aminopropane([¹²⁵I]DOI) binding to 5-HT₂ and 5-HT_{1C} receptors in rat brain. *J Pharmacol Exp Ther* 255:843–857
- Barnes NM, Sharp T (1999): A review of central 5-HT receptors and their function. *Neuropharmacol* 38:1083–1152
- Bymaster FP, Shannon HE, Rasmussen K, DeLapp NW, Ward JS, Calligaro DO, Mitch CH, Whitesitt C, Ludvigsen TS, Sheardown M, Swedberg M, Rasmussen T, Olesen PH, Jeppesen L, Sayerberg P, Fink-Jensen A (1999): Potential role of muscarinic receptors in schizophrenia. *Life Sci* 64:527–534
- [conf]Carr AA, Hay DD, Dudley MW, Kehne JH, Nieduzak TR (1991): MDL 28,133A and related α -aryl-4-piperidinyl methanols and ketones as potent and selective inhibitors of serotonin 5-HT₂ receptors. Abstracts of the III International Congress on Schizophrenia Research, Tucson, AZ
- Davis KL, Kahn RS, Grant K, Davidson M (1991): Dopamine in schizophrenia: a review and reconceptualization. *Am J Psychiat* 148:1474–1486
- De Deurwaerdère P, Spampinato U (1999): Role of serotonin_{2A} and serotonin_{2B/2C} receptor subtypes in the control of accumbal and striatal dopamine release elicited in vivo by dorsal raphe nucleus electrical stimulation. *J Neurochem* 73:1033–1042
- Dewey SL, Smith GS, Logan J, Brodie JD, Fowler JS, Wolf AP (1993): Striatal binding of the PET ligand ¹¹C-raclopride is altered by drugs that modify synaptic dopamine levels. *Synapse* 13:350–356
- Di Giovanni G, De Deurwaerdère P, Di Mascio M, Di Matteo V, Esposito E, Spampinato U (1999): Selective blockade of serotonin_{2C/2B} receptors enhances mesolimbic and mesostriatal dopaminergic function: a combined in vivo electrophysiological and microdialysis study. *Neurosci* 91:587–597
- Di Giovanni G, Di Matteo V, Di Mascio M, Esposito E (2000): Preferential modulation of mesolimbic vs. nigrostriatal dopaminergic function by serotonin_{2C/2B} receptor agonists: a combined in vivo electrophysiological and microdialysis study. *Synapse* 35:53–61
- Di Matteo V, Di Giovanni G, Di Mascio M, Esposito E (1999): SB 242084, a selective serotonin_{2C} receptor antagonist, increases dopaminergic transmission in the mesolimbic system. *Neuropharmacol* 38:1195–1205
- Di Matteo V, Di Mascio M, Di Giovanni G, Esposito E (2000a): Acute administration of amitriptyline and mianserin increases dopamine release in the rat nucleus accumbens: possible involvement of serotonin_{2C} receptors. *Psychopharmacol* 150:45–51
- Di Matteo V, Di Giovanni G, Di Mascio M, Esposito E (2000b): Biochemical and electrophysiological evidence that Ro 60-0175 inhibits mesolimbic dopaminergic function through serotonin_{2C} receptors. *Brain Res* 865:85–90
- Di Matteo V, De Blasi A, Di Giulio C, Esposito E (2001): Role of 5-HT_{2C} receptors in the control of central dopamine function. *Trends Pharmacol Sci* 22:229–232
- Gobert A, Millan MJ (1999): Serotonin (5-HT)_{2A} receptor activation enhances dialysis levels of dopamine and noradrenaline, but not 5-HT, in the frontal cortex of freely moving rats. *Neuropharmacol* 38:315–317
- Gobert A, Rivet J-M, Lejeune F, Newman-Tancredi A, Adhumeau-Auclair A, Nicolas J-P, Cistarelli L, Melon C, Millan MJ (2000): Serotonin_{2C} receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: A combined dialysis and electrophysiological analysis in the rat. *Synapse* 36:205–221
- Goff DC, Amico E, Dreyfuss D, Ciraulo D (1995): A placebo-controlled trial of trihexyphenidyl in unmedicated patients with schizophrenia. *Am J Psychiat* 151: 429–431
- Hall H, Farde L, Halldin C, Lundkvist C, Sedvall G (2000): Autoradiographic localization of 5-HT_{2A} receptors in the human brain using [³H]M100907 and [¹¹C]M100907. *Synapse* 38:421–431
- Hertel P, Fagerquist MV, Svensson TH (1999): Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by α_2 adrenoceptor blockade. *Science* 286: 105–107
- Hicks PB, Browning J, Barwick S, Jones D, Wadenberg M-L, Richter JT, Young KA (1999): M100,907 acts both the nucleus accumbens and the prefrontal cortex to mediate the enhancement of the suppression of conditioned avoidance response by haloperidol. *Schizophr Res* 36: 115
- Ichikawa J, Meltzer HY (1999a): Relationship between

- dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs. *Eur Arch Psychiat Clin Neurosci* 249(Suppl 4):S90–S98
- Ichikawa J, Meltzer HY (1999b): R(+)-8-OH-DPAT, a serotonin_{1A} receptor agonist, potentiated S(-)-sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum. *J Pharmacol Exp Ther* 291:1227–1232
- Ichikawa J, Meltzer HY (2000): The effect of serotonin_{1A} receptors on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens. *Brain Res* 858:252–263
- Ichikawa J, Ishii H, Bonaccorso S, O'Laughlin IA, Fowler WL, Meltzer HY (2001a): 5-HT_{2A} and D₂ receptor blockade increases cortical DA release via of 5-HT_{1A} receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. *J Neurochem* 76:1521–1531
- Ichikawa J, Dai J, Meltzer HY (2001b): DOI, a 5-HT_{2A/2C} receptor agonist, attenuates clozapine-induced cortical dopamine release. *Brain Res* 907:151–155
- Ichikawa J, Dai J, O'Laughlin IA, Fowler WL, Meltzer HY (2002): Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. *Neuropsychopharmacology* 26:325–339
- Kehne JH, Baron BM, Carr AA, Chaney SF, Elands J, Feldman DJ, Frank RA, Van Giersbergen PLM, McCloskey TC, Johnson MP, Maccarty DR, Poirot M, Senyah Y, Siegel BW, Widmaier C (1996): Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT_{2A} antagonist with a favorable CNS safety profile. *J Pharmacol Exp Ther* 277:968–981
- Kuroki T, Meltzer HY, Ichikawa J (1999): Effect of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. *J Pharmacol Exp Ther* 288:774–781
- Li X-M, Perry KW, Wong DT, Bymaster FP (1998): Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. *Psychopharmacol* 136:153–161
- Liégeois J-F, Ichikawa J, Meltzer HY (2002): 5-HT_{2A} receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. *Brain Res* (in press)
- Lucas G, Spampinato U (2000): Role of striatal serotonin_{2A} and serotonin_{2C} receptor subtypes in the control of in vivo dopamine outflow in the rat striatum. *J Neurochem* 74:693–701
- Lucas G, De Deurwaerdère P, Caccia S, Spampinato U (2000): The effect of serotonergic agents on haloperidol-induced striatal dopamine release in vivo: opposite role of 5-HT_{2A} and 5-HT_{2C} receptor subtypes and significance of the haloperidol dose used. *Neuropharmacol* 39:1053–1063
- Matsubara S, Matsubara R, Kusumi I, Koyama T, Yamashita I (1993): Dopamine D₁, D₂ and serotonin₂ receptor occupancy by typical and atypical antipsychotic drugs in vivo. *J Pharmacol Exp Ther* 265:498–508
- Meltzer HY, Matsubara S, Lee JC (1989): Classification of typical and atypical antipsychotic drugs on the basis of dopamine D₁, D₂ and serotonin₂ pKi values. *J Pharmacol Exp Ther* 251:238–246
- Meltzer HY (1999): The role of serotonin in antipsychotic drug action. *Neuropsychopharmacol* 21:106S–115S
- Meltzer HY, McGurk SR (1999): The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. *Schizophr Bull* 25:233–255
- Millan MJ, Dekeyne A, Gobert A (1998): Serotonin (5-HT)_{2C} receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo. *Neuropharmacol* 37:953–955
- Moghaddam B, Bunney BS (1990): Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. *J Neurochem* 54:1755–1760
- Morilak DA, Garlow SJ, Ciaranello RD (1993): Immunocytochemical localization and description of neurons expressing serotonin₂ receptors in the rat brain. *Neurosci* 54:701–717
- Nomikos GG, Iurlo M, Andersson JL, Kimura K, Svensson TH (1994): Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex. *Psychopharmacol* 115:147–156
- Paxinos G, Watson C (1986): *The Rat Brain in Stereotaxic Coordinates*. New York, Academic Press
- Pehek EA (1996): Local infusion of the serotonin antagonists ritanserin or ICS 205,930 increases in vivo dopamine release in the rat medial prefrontal cortex. *Synapse* 24:12–18
- Pehek EA, McFarlane HG, Maguschak K, Price B, Pluto CP (2001): M100,907, a selective 5-HT_{2A} antagonist, attenuates dopamine release in the rat medial prefrontal cortex. *Brain Res* 888:51–59
- Rausser L, Savage JE, Meltzer HY, Roth BL (2001): Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-Hydroxytryptamine_{2C} receptor. *J Pharmacol Exp Ther* 299:83–89
- Rinaldi-Carmona M, Congy C, Santucci V, Simiand J, Gautret B, Neliat G, Labeeuw B, Le Fur G, Soubrie P, Breliere JC (1992): Biochemical and pharmacological properties of SR 46349B, a new potent and selective 5-HT receptor antagonist. *J Pharmacol Exp Ther* 262:759–768
- Rollema H, Lu Y, Schmidt AW, Sprouse J, Zorn SH (2000): 5-HT_{1A} receptor activation contributes to ziprasidone-induced dopamine release in rat prefrontal cortex. *Biol Psychiat* 48:229–237
- Roth BL, Ciaranello RD, Meltzer HY (1992): Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT_{1C} receptors. *J Pharmacol Exp Ther* 260:1361–1365
- Ruiu S, Marchese G, Saba PL, Gessa GL, Pani L (2000): The 5-HT₂ antagonist ritanserin blocks dopamine re-uptake in the rat frontal cortex. *Mol Psychiat* 5:673–677
- Schotte A, Janssen PFM, Gommeren W, Luyten WHML, Van Gompel P, Lesage AS, De Loore K, Leysen JE (1996): Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. *Psychopharmacol* 124:57–73

- Seeman P, Niznik HB, Guan HC, Booth G, Ulpian C (1989): Link between D₁ and D₂ dopamine receptors is reduced in schizophrenia and Huntington diseased brain. *Proc Natl Acad Sci* 86:10156–10160
- Shipley J (1998): M100907 Phase IIB Trial. Presented at Hoechst Marion Roussel Conference on M100907, West Palm Beach Florida, April 1998
- Spampinato U, De Deurwaerdère P, Caccia S, Lucas G (1998): Opposite role of central 5-HT_{2A} and 5-HT_{2C} receptors subtypes in the control of haloperidol-induced release of dopamine in the rat striatum. *Soc Neurosci Abstr* 24(48.4):108
- Stockmeier CA, Di Carlo JJ, Zhang Y, Thompson P, Meltzer HY (1993): Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin₂ and dopamine₂ receptors. *J Pharmacol Exp Ther* 266:1374–1384
- Tandon R (1999): Cholinergic aspects of schizophrenia. *Br J Psychiat* 174:Suppl 37:7–11
- Talvik-Lotfi M, Nyberg S, Nordström A-L, Ito H, Halldin C, Brunner F, Farde L (2000): High 5HT_{2A} receptor occupancy in M100907-treated schizophrenic patients. *Psychopharmacol* 148:400–403
- Tsukada H, Nishiyama S, Kakiuchi T, Ohba H, Sato K, Harada N (1999): Is synaptic dopamine concentration the exclusive factor which alters the in vivo binding of [¹¹C]raclopride?: PET studies combined with microdialysis in conscious monkeys. *Brain Res* 841:160–169
- Wadenberg M-L, Hicks PB, Richter JT, Young KA (1998): Enhancement of antipsychotic-like properties of raclopride in rats using the selective serotonin_{2A} receptor antagonist MDL 100,907. *Biol Psychiat* 44:508–515
- Wadenberg M-L, Browning JL, Young KA, Hicks PB (2001): Antagonism at 5-HT_{2A} receptors potentiates the effect of haloperidol in a conditioned avoidance response task in rats. *Pharmacol Biochem Behav* 68:363–370
- Weiner DM, Burstein ES, Nash N, Croston GE, Currier EA, Vanover KE, Harvey SC, Donohue E, Hansen HC, Andersson CM, Spalding TA, Gibson DFC, Krebs-Thomson K, Powell SB, Geyer MA, Hacksell U, Brann MR (2001): 5-Hydroxytryptamine_{2A} receptor inverse agonists as antipsychotics. *J Pharmacol Exp Ther* 299:268–276
- Westerink BH, Kawahara Y, De Boer P, Geels C, De Vries JB, Wikstrom HV, Van Kalker A, Van Vliet B, Kruse CG, Long SK (2001): Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum. *Eur J Pharmacol* 412:127–138
- Wiesel F-A, Nordström A-L, Farde L, Eriksson B (1994): An open clinical and biochemical study of ritanserin in acute patients with schizophrenia. *Psychopharmacol* 114:31–38
- Yan Q-S (2000): Activation of 5-HT_{2A/2C} receptors within the nucleus accumbens increases local dopaminergic transmission. *Brain Res Bull* 51:75–81
- Yan Q-S, Reith MEA, Yan S (2000): Enhanced accumbal dopamine release following 5-HT_{2A} receptor stimulation in rats pretreated with intermittent cocaine. *Brain Res* 863:254–258
- Zhang W, Perry KW, Wong DT, Potts BD, Bao J, Tollefson GD, Bymaster FP (2000): Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. *Neuropsychopharmacol* 23:250–262